

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-22. (Cancelled)

23. (Previously presented) A method of inhibiting binding of IL-13 to the IL-13 receptor in a mammalian subject having an allergen-induced airway hyper responsiveness, said method comprising

administering a polypeptide encoded by a polynucleotide that hybridizes under conditions comprising hybridization at 65⁰C in 0.1x SSC to the complement of the portion of SEQ ID NO:3 that encodes from amino acid 26 to amino acid 341 of SEQ ID NO:4, wherein said polypeptide is administered in an amount sufficient to inhibit binding of IL-13 to the IL-13 receptor.

24-27. (Cancelled)

28. (Previously presented) A method of treating an allergen-induced airway hyper responsiveness in a mammalian subject, said method comprising administering a therapeutically effective amount of a polypeptide encoded by a polynucleotide that hybridizes under conditions comprising hybridization at 65⁰C in 0.1x SSC to the complement of the portion of SEQ ID NO:3 that encodes from amino acid 26 to amino acid 341 of SEQ ID NO:4.

29-47. (Cancelled)

48. (Previously presented) The method of claim 23, wherein said polypeptide comprises from amino acid 26 to amino acid 341 of SEQ ID NO:4.

49. (Previously presented) The method of claim 23, wherein said polypeptide is part of a fusion protein.

50. (Previously presented) The method of claim 49, wherein said fusion protein comprises an antibody fragment.

51. (Previously presented) The method of claim 50, wherein said antibody fragment includes an Fc fragment.

52. (Previously presented) The method of claim 48, wherein said polypeptide is part of a fusion protein.

53. (Previously presented) The method of claim 52, wherein said fusion protein comprises an antibody fragment.

54. (Cancelled)

55. (Previously presented) The method of claim 48, wherein said polypeptide comprises amino acids 26-341 of SEQ ID NO:4.

56-58. (Cancelled)

59. (Previously presented) The method of claim 28, wherein said polypeptide comprises from amino acid 26 to amino acid 341 of SEQ ID NO:4.

60. (Previously presented) The method of claim 28, wherein said polypeptide is part of a fusion protein.

61. (Previously presented) The method of claim 60, wherein said fusion protein comprises an antibody fragment.

62. (Previously presented) The method of claim 59, wherein said polypeptide is part of a fusion protein.

63. (Cancelled)

64. (Currently amended) The method of claim ~~[[57]]~~28, wherein said polypeptide comprises from amino acid 26 to amino acid 341 of SEQ ID NO:4.

65. (Previously presented) The method of claim 64, wherein said polypeptide is part of a fusion protein.

66. (Previously presented) The method of claim 65, wherein said fusion protein comprises an antibody fragment.

67. (Previously presented) The method of claim 66, wherein said antibody fragment includes an Fc fragment.

68. (New) A method of administering a polypeptide to a mammalian subject having allergen-induced airway hyper responsiveness, said method comprising administering a therapeutically effective amount of a polypeptide encoded by a polynucleotide that hybridizes under conditions comprising hybridization at 65⁰C in 0.1x SSC to the complement of the portion of SEQ ID NO:3 that encodes from amino acid 26 to amino acid 341 of SEQ ID NO:4, wherein said polypeptide is administered by oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection.